There is an outfit in Columbia, Maryland that makes nutritional substances from microbes. It sounds odd, but the stuff must be good. It is found in almost ninety percent of all U.S. infant formulas.

Martek Biosciences Corporation (NASDAQ: MATK) provides natural products derived from microalgae, fungi and other microbes. These include nutritional oils, which are used by makers of infant formula, nutritional supplements, and food and beverage fortification products. Martek also offers contract manufacturing services for the production of enzymes, specialty chemicals, vitamins and agricultural specialty products. Further, it provides fluorescent detection products, used by researchers in drug discovery and diagnostics. Customers include Dean Foods (NYSE: DF), General Mills (NYSE: GIS) and Kellogg (NYSE: K).

The firm pleased investors last week, when it reported Q4 EPS of 23 cents and revenues of $82 million. Analysts had been expecting 20 cents and $78.4 million. Management also guided Q1 EPS to 21-23 cents (17 cent consensus) and Q1 revenues to $79-83 million ($77.30M consensus). For FY08, the company expects year over year growth in both revenues and profitability.

There is an outfit in Columbia, Maryland that makes nutritional substances from microbes. It sounds odd, but the stuff must be good. It is found in almost 90% of all U.S. infant formulas.

Martek Biosciences Corporation (NASDAQ: MATK) provides natural products derived from microalgae and fungi. These include nutritional oils, which are used by makers of infant formula, nutritional supplements, and food and beverage fortification products. Martek also offers contract manufacturing services for the production of enzymes, specialty chemicals, vitamins and agricultural specialty products. Further, it provides fluorescent detection products, used by researchers in drug discovery and diagnostics. Customers include Dean Foods Co. (NYSE: DF), General Mills Inc. (NYSE: GIS) and Kellogg Company (NYSE: K).

The firm pleased investors last week, when it reported Q2 EPS of 15 cents and revenues of $76.7 million. Analysts had been expecting 15 cents and $76.3 million. Management also guided Q3 EPS to 18-21 cents (17 cent consensus), Q3 revenues to $77-$80 million ($77.90M consensus), FY07 EPS to 62-66 cents (61 cent consensus) and FY07 revenues to $301-$306 million ($301.67M consensus). MATK shares popped through 200-day moving average resistance into the initial stage of a bullish "flag" consolidation pattern on the news. Prices frequently exit flags moving in the same direction they were traveling when they entered them. In this case, that would be to the upside. Note that the move into the flag completes the formation of a "double bottom" pattern, another bullish sign of further gains.

Brokers recommend the issue with two "buys," one "hold" and one "sell." Analysts expect a 35% growth rate through the next year. The MATK Price to Sales ratio (2.78) and Price to Book ratio (1.56) compare favorably with industry, sector and S&P 500 averages. Institutional investors hold about 82% of the outstanding shares. The stock is one of those used to calculate the S&P 400 MidCap Index. Over the past 52 weeks, it has traded between $19.64 and $30.84. A stop-loss of $19.95 looks good here.

Larry Schutts is a contributing editor for Theflyonthewall.com and the Vice-President of Stockwinners.com.